Atopic dermatitis (AD) is a chronic skin inflammatory disease affecting 10-20% of children worldwide. The etiology of AD is incompletely understood, but many elements (e.g., genetic, environmental or immune) are thought to contrib...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
IMMCEPTION
Nociception and sensory nerves as regulators of type 2 immun...
1M€
Cerrado
Mast cells in eczema
Study of the role of mast cells in the modulation of immune...
257K€
Cerrado
NEUROSKIN
Modulating skin innervation to treat cutaneous inflammation
150K€
Cerrado
PID2020-114652RB-I00
SEÑALIZACION MEDIADA POR LOS RECEPTORES DE CORTICOSTEROIDES:...
169K€
Cerrado
4D-SkINFLAM
Spatio-temporal integration of skin inflammation
2M€
Cerrado
MOLINFLAM
Molecular dissection of inflammatory pathways
1M€
Cerrado
Información proyecto NEMESIS
Duración del proyecto: 24 meses
Fecha Inicio: 2017-06-16
Fecha Fin: 2019-06-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Atopic dermatitis (AD) is a chronic skin inflammatory disease affecting 10-20% of children worldwide. The etiology of AD is incompletely understood, but many elements (e.g., genetic, environmental or immune) are thought to contribute to the pathogenesis. The skin is specifically enriched in mast cells (MCs) and innervated by a network of abundant sensory neurons. New findings suggest that nociceptive sensory neurons (nociceptors) might regulate the development of immune responses. Skin MCs also express a transcriptional signature of genes encoding neuropeptide receptors (e.g., Mrgprb2: the receptor for the substance P [SP]), through which MCs might uniquely interact with nociceptors. Based on solid preliminary data, the central hypothesis of this project is that SP-producing nociceptor/Mrgprb2+ MC interactions play a critical role in AD pathogenesis. Using a relevant mouse model of AD and innovative imaging approaches, we now aim to elucidate [1] which subset(s) of nociceptor is involved in AD, [2] how SP+ nociceptor/Mrgprb2+ MC interact in our model and in skin lesions from patients diagnosed with AD and [3] how such interactions might favor skin barrier dysfunction. This project promises to provide new insights into skin neuro-immune interactions and may lead to the discovery of new therapeutic targets to treat AD pathology.